http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2013110876-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-526 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-624 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2896 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-468 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-461 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00 |
| filingDate | 2011-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2014-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2013110876-A |
| titleOfInvention | ACTIVATED SPECIFIC ANTIBODIES |
| abstract | 1. A bispecific antibody, comprising: a) a first antibody that binds to the first antigen, comprising the VH domain and VL domain, and b) a second antibody that binds to the second antigen, where the VH domain is connected via its N-terminus through the first peptide linker to the second antibody and the VL domain is connected through its N-end via a second peptide linker with a second antibody, and the bispecific antibody is characterized in that: one of the linkers contains a protease cleavage site specific for the tumor or inflammation, and the other the linker does not contain a protease cleavage site; the binding affinity of the bispecific antibody to the first antigen is reduced by 5 times or more compared to the corresponding bispecific antibody in which the protease cleavage site was cleaved. 2. The bispecific antibody according to claim 1, characterized in that: the second antibody is a whole antibody; the VL domain is connected through its N-end via the first linker with the C-terminus of the first heavy chain of the second antibody, the VH domain is connected through its N-end by the second linker with the C-terminus of the second heavy chain of the second antibody. 3. The bispecific antibody according to claim 2, characterized in that it contains the following polypeptide chains (indicating the order of the domains from the C- to the N-terminus): one chain VH-peptide linker-CH3-CH2-CH1-VH; - two CL-VL chains; - one chain VL-peptide linker-CH3-CH2-CH1-VH. 4. The bispecific antibody according to claim 2, characterized in that: the first CH3 domain of the whole chain of the whole antibody and the second CH3 domain of the whole antibody are connected to each other, forming a contact surface that contains changes from |
| priorityDate | 2010-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 42.